Literature DB >> 15818867

[Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines].

.   

Abstract

Mesh：

Year:  2004        PMID： 15818867

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  22 in total

1.  Multicenter prospective study of sublobar resection for c-stage I non-small cell lung cancer patients unable to undergo lobectomy (KLSG-0801): complete republication.

Authors:  Nobumasa Takahashi; Noriyoshi Sawabata; Masafumi Kawamura; Takashi Ohtsuka; Hirotoshi Horio; Hirozou Sakaguchi; Mitsuo Nakayama; Katsuo Yoshiya; Masayuki Chida; Eishin Hoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-27

2.  Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study.

Authors:  Yasunari Hiramine; Hirofumi Uto; Yasushi Imamura; Kazuaki Tabu; Yoshirou Baba; Takuya Hiwaki; Yukihiko Sho; Kenji Tahara; Hirofumi Higashi; Tutomu Tamai; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

3.  Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer.

Authors:  Taro Fukui; Koichi Suzuki; Kosuke Ichida; Yuji Takayama; Nao Kakizawa; Yuta Muto; Fumi Hasegawa; Fumiaki Watanabe; Rina Kikugawa; Masaaki Saito; Shingo Tsujinaka; Yasuyuki Miyakura; Toshiki Rikiyama
Journal:  Oncol Lett       Date:  2017-04-26       Impact factor: 2.967

4.  Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.

Authors:  Hiroyuki Iwasaki; Haruhiko Yamazaki; Hirotaka Takasaki; Nobuyasu Suganuma; Hirotaka Nakayama; Soji Toda; Katsuhiko Masudo
Journal:  Oncol Lett       Date:  2018-10-05       Impact factor: 2.967

5.  Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Seiko Bun; Mayu Yunokawa; Yoshiko Tamaki; Akihiko Shimomura; Tatsunori Shimoi; Makoto Kodaira; Chikako Shimizu; Kan Yonemori; Yasuhiro Fujiwara; Yoshinori Makino; Hiroyuki Terakado; Kenji Tamura
Journal:  Support Care Cancer       Date:  2018-01-25       Impact factor: 3.603

6.  Feasibility of 5-days-on/2-days-off UFT/leucovorin in post-operative long-term adjuvant chemotherapy for colorectal cancer.

Authors:  Yukihiko Tokunaga; Hirokazu Sasaki
Journal:  Oncol Lett       Date:  2012-02-02       Impact factor: 2.967

7.  Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.

Authors:  Masako Imazawa; Takashi Kojima; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Hirofumi Yasui; Kentaro Yamazaki; Keisei Taku
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

8.  GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.

Authors:  Elizabeth Ann Coleman; Jeannette Y Lee; Stephen W Erickson; Julia A Goodwin; Naveen Sanathkumar; Vinay R Raj; Daohong Zhou; Kent D McKelvey; Senu Apewokin; Owen Stephens; Carol A Enderlin; Annette Juul Vangsted; Patty J Reed; Elias J Anaissie
Journal:  Support Care Cancer       Date:  2014-09-14       Impact factor: 3.603

9.  Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

Authors:  Rai Shimoyama; Hirofumi Yasui; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Kentaro Yamazaki; Keisei Taku; Takashi Kojima; Nozomu Machida; Akiko Todaka; Hideharu Tomita; Takeshi Sakamoto; Takahiro Tsushima
Journal:  Gastric Cancer       Date:  2010-01-05       Impact factor: 7.370

10.  Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.

Authors:  T Yoshioka; S Kato; M Gamoh; N Chiba; T Suzuki; N Sakayori; S Kato; H Shibata; H Shimodaira; K Otsuka; Y Kakudo; S Takahashi; C Ishioka
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.